After years of funding disease-specific treatment, donation trends have shifted to support broader health systems infrastructure development. A remaining challenge is how to sustain antiretroviral therapy (ART) for patients in resource-poor regions.
AMA J Ethics. 2016;18(7):681-690. doi:
10.1001/journalofethics.2016.18.7.ecas3-1607.
In cost-effectiveness research, the cost of a medical intervention is reported as a dollar amount per quality-adjusted life year gained—the quality of health and the length of time over which the health state exists.
Hilary Daniel joins Ethics Talk to discuss her article, coauthored with Courtney Perlino and Dr Amy B. Cadwallader: “Which Drugs Should Be on the Essential Medicines List?”
LaPrincess C. Brewer, MD, MPH and Lisa A. Cooper, MD, MPH
Stressful life experience associated with racial and ethnic discrimination can have detrimental effects on the coronary and cardiovascular health of people in historically marginalized groups.
Extending immunosuppressive drug coverage for the lifetime of kidney patients, instead of only covering dialysis, would be a cost-effective way for the federal government to reduce the costs of posttransplant care while improving clinical outcomes for patients.